Searched for
CANCER DRUG PRICE CUT
NPPA list brings little relief: No price cut for 25% cancer drugsNearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across ...- India’s drug pricing policy must balance affordability, medicine availability and pharma industry growthThe Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussi...
- Anti-cancer medicines: How to protect the patient today without weakening India's healthcare capacity for tomorrowIndia should examine trade margins across medicines, medical devices and consumables using a common, scientifically credible method - not a...
- India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: PharmexcilIndia's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driv...
- Cancer drug price cuts leave costly brands untouchedPrices of several anti-cancer drugs are set to fall significantly starting November 9, offering some financial relief. However, the prices ...
- Cancer care can be cheaper: 6 steps to cut drug costsIndia has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care,...
- Anthropic's Claude cut Enveda's drug records' review time by 89%Colorado-based biotechnology company Enveda developed a CMC Document Processor to help reviewers identify errors, inconsistencies and poten...
- Cipla sets sights on first-wave gains from rollout of Keytruda BiosimilarCipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for t...
- SC pulls up Centre over soaring medicine costsThe Supreme Court expressed concern over the government's role in allowing steep medicine prices to persist. Justices Vikram Nath and Sande...
- Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% r...
- Dr Reddy's bets on generic semaglutide, biosimilarsDr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of gene...
- Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trialJohnson & Johnson reported results from an early-stage trial of their prostate cancer drug JNJ-6143. The trial involved patients with advan...
- DRL says cap on trade margins a positive, posts 36% dip in Q2 PATIn the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trad...
- Pathos AI teams up with Bristol Myers and Tempus AI to advance drug developmentPathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence too...
- Hospitals overcharge patients upto 700% on medicines while India makes some of the world’s lowest priced drugs: Centre admits to SCGovt has told Supreme Court that hospitals overcharging patients for medicines and medical consumables is a malpractice. Its affidavit cite...
- Sanofi healthcare receives CDSCO approval for Qftilia therapy for haemophilia patients in IndiaSanofi Healthcare has obtained authorisation from the Central Drugs Standard Control Organisation for Qfitlia. This therapy is designed to ...
- NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov 9India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. ...
- The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reachFor millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...
- Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possibleAn expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...
- SC asks govt to broaden inflated pricing review beyond oncologyThe Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...
Load More
